ArticleBMC microbiology2026
Susceptibility to novel antimicrobial agents and molecular epidemiology of carbapenem-resistant enterobacterales: a 9-year study in Central China.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
purposeThis nine-year (2016-2024) surveillance study aimed to investigate the molecular epidemiology and antimicrobial susceptibility profiles of carbapenem-resistant Enterobacterales (CRE) in a tertiary hospital in Central China, with a focus on evaluating the in vitro efficacy of novel antimicrobial agents.
methodsAntimicrobial susceptibility testing was conducted by broth microdilution to identify CRE isolates. From 1,403 non-duplicate CRE isolates(representing 13.4% of all Enterobacterales isolates recovered during the study period), 133 representative strains were selected for comprehensive molecular analysis. Carbapenemase genes were detected by PCR and sequencing, and multilocus sequence typing (MLST) was performed.
resultsAmong the 1,403 CRE isolates, carbapenem-resistant Klebsiella pneumoniae (CRKP) predominated (65.5%). In the 133-strain subset, 97.7% harbored carbapenemase genes, primarily blaKPC-2 (82.7%). Cefiderocol and aztreonam-avibactam demonstrated 100% susceptibility against all tested strains. Against blaKPC-2 producers, susceptibility rates to ceftazidime-avibactam, imipenem-relebactam, and meropenem-vaborbactam were 92.7%, 96.4%, and 97.3%, respectively. The high-risk CRKP-ST11-blaKPC-2 clone dominated (81.2% of CRKP). Notably, 44.4% (8/18) of NDM-producing isolates and one IMP-4-producing isolate were susceptible to meropenem-vaborbactam, associated with low-level carbapenem resistance and absence of co-produced serine β-lactamases. Temporal variation in CRE proportion was observed, with a decline during 2020-2022 and an increase after 2023.
conclusionThe CRKP-ST11-blaKPC-2 clone is the primary driver of CRE dissemination in our setting, highlighting the need for sustained infection control. Ceftazidime-avibactam, imipenem-relebactam, and meropenem-vaborbactam showed excellent activity against KPC producers, while cefiderocol and aztreonam-avibactam demonstrated potent activity against all CRE tested, including metallo-β-lactamase producers. The susceptibility of some NDM and IMP-4 producers to meropenem-vaborbactam underscores the heterogeneity within MBL-producing Enterobacterales and the importance of phenotypic susceptibility testing. Clinical studies are warranted to confirm the real-world efficacy and safety of these novel agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.